Who Is Using The VAP
Our Working Relationships
Atherotech has been involved in research testing for more than 100 clinical research studies and trials with institutions and organizations including:
- AstraZeneca
- AtheroGenics
- Ball State University
- Baylor College of Medicine
- Boston University School of Medicine
- Cincinnati Children’s Hospital
- Creighton University
- Duke University
- Emory School of Medicine
- Esoterix-LabCorp
- Genzyme Diagnostics
- GlaxoSmithKline
- International Institute for Biomedical Research
- Johns Hopkins
- Mayo Medical Laboratories
- Merck
- Merck Sharpe & Dohme
- Memorial Sloane-Kettering
- Metabasis
- Microbia
- National Institute of Health
- Oregon Research Institute
- Pfizer
- San Jose State University
- Stanford University
- Texas A&M University
- Texas Children’s Hospital
- The Medical College of Georgia
- The University of Alabama
- The University of Alabama at Birmingham
- The University of Calgary
- The University of California at San Diego
- The University of California at San Francisco
- The University of Colorado
- The University of Maryland
- The University of Minnesota Medical Center
- The University of Nevada at Reno
- The University of New Mexico
- The University of Pittsburgh
- The University of Rochester Medical Center
- The University of South Florida
- The University of Utah
- The University of Virginia
- The University of Washington
- Vanderbilt University
- Yale University School of Medicine
Our Research and Development Director
Kris Kulkarni, Ph.D., has been our director since 1999, specializing in testing cardiovascular risk markers. Prior to joining Atherotech, Dr. Kulkarni was with the Department of Medicine at the University of Alabama in Birmingham for 12 years. He began his career there as a postdoctoral fellow, rising to the position of Research Assistant Professor of Medicine. He was involved in every phase of the development of the VAP© Test. Dr. Kulkarni is a member of the American Association of Clinical Chemistry (AACC) and has published extensively.
